Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin

Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations

(2017) Ruijuan Luo et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes

(2017) Dora Mehn et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Liposomal Formulations in Clinical Use: An Updated Review

(2017) Upendra Bulbake et al.   Pharmaceutics

A novel photoelectrochemical immunosensor by integration of nanobody and TiO 2 nanotubes for sensitive detection of serum cystatin C

(2016) Li Mi et al.   ANALYTICA CHIMICA ACTA

Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches

(2016) Alireza Farasat et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Antibody-targeted biodegradable nanoparticles for cancer therapy

(2016) Vahid Heravi Shargh et al.   Nanomedicine

Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein

(2016) Jing Chen et al.   TALANTA

Determination of Key Parameters for a Mechanism-Based Model to Predict Doxorubicin Release from Actively Loaded Liposomes

(2015) Eva Csuhai et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy

(2015) Paolo Nuciforo et al.   Molecular Oncology

In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site

(2015) Lisa Silverman et al.   Nanomedicine-Nanotechnology Biology and Medicine

A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment

(2014) Zahra Farajpour et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling

(2014) M. Pruszynski et al.   JOURNAL OF NUCLEAR MEDICINE

Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies

(2014) Selma Djender et al.   Microbial Cell Factories

Development and Characterization of Liposomal Doxorubicin Hydrochloride with Palm Oil

(2014) Bahareh Sabeti et al.   Biomed Research International

Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells

(2012) Fatemeh Rahimi Jamnani et al.   EXPERIMENTAL CELL RESEARCH

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

(2011) Ilse Vaneycken et al.   FASEB JOURNAL

Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer

(2010) Anna Emde et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies

(2010) Tomohiro Makino et al.   METABOLIC ENGINEERING

Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes

(2009) Jie Gao et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties

(2009) Daniel Zucker et al.   JOURNAL OF CONTROLLED RELEASE

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

(2009) T. Ben-Kasus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A review of stimuli-responsive nanocarriers for drug and gene delivery

(2008) Srinivas Ganta et al.   JOURNAL OF CONTROLLED RELEASE

In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells

(2008) Ken-ichi Ogawara et al.   JOURNAL OF CONTROLLED RELEASE